News & Updates

Treatment comprising camrelizumab, carboplatin, and paclitaxel in the first-line setting improved overall survival (OS) in patients with advanced squamous non-small-cell lung cancer (NSCLC), according to updated results of the phase III CameL-sq trial from China.

A recent study assessing the diagnostic and management processes of polycystic ovary syndrome (PCOS) adopted by clinicians from different specialties in Singapore has found certain variations, which warrant the need for standardized workplace protocols and patient education resources.

Administration of oral silymarin leads to a substantial decrease in hepatotoxicity severity after 1 month of treatment in nonmetastatic breast cancer patients on doxorubicin/cyclophosphamide-paclitaxel (AC-T) regimen, reports a study.

In patients with relapsed/refractory multiple myeloma (R/R MM), a combination of melflufen and dexamethasone proved better than an approved doublet standard-of-care (SoC) comprising pomalidomide-dexamethasone in terms of progression-free survival (PFS), the phase III OCEAN trial has shown. However, the overall survival (OS) outcome with the melflufen-containing regimen appeared to digress from the PFS result, potentially casting doubt on its benefit for this condition.

When used in addition to standard of care, favipiravir leads to faster viral clearance and clinical improvement time among patients hospitalized with COVID-19, although it appears to contribute to an increased risk of hyperuricaemia, according to the results of a meta-analysis